do you point out this company without sounding like "over-hyping" NVGN ??
Good ex. of what these drug discovery companies can do, before even entering Phase 3. I always laugh when i see some who think NVGN won't see any pps appreciation, until Phase 3.....the end, of Phase 3. Especially when you can only sell & not buy NVGN, on-line through E-trade.
Keep in mind, Esperion is just a one trick-pony.
" Shares of Esperion closed Monday up 14.1% at $75.51 in its 52-week trading range of $15.00 to $120.96."